Overview
- The Supreme Court, acting Thursday, let mifepristone continue by telehealth and mail nationwide by staying a May 1 ruling that had revived an in‑person pickup rule.
- Justices Samuel Alito and Clarence Thomas dissented, arguing the majority offered no reasoning and asserting mail distribution conflicts with state abortion bans.
- Drugmakers Danco Laboratories and GenBioPro sought the emergency stay after the 5th Circuit’s order, warning of immediate confusion for patients, providers and pharmacies.
- Louisiana’s lawsuit challenges the FDA’s 2023 policy allowing remote prescribing and mailing, claiming the rule thwarts its abortion ban and raises Medicaid costs.
- The FDA is conducting a safety review of mifepristone, so future agency action could still change how the drug is prescribed and delivered.